Haemostasis Q4 2025 Journal Club

Keep informed about evolving science and clinical practice with our compilation of the latest studies, guidelines, and perspectives in haemostasis.

GUIDELINES

• Jennings I, Baker P, Bowyer A, et al. Reporting haemostasis assays in IU/dL-A recommendation for harmonisation from the British Society for Haematology Haemostasis and Thrombosis Task Force, UK NEQAS for Blood Coagulation and the UK Haemophilia Centres Doctors Organisation. Br J Haematol. 2025;207(4):1698-1701. doi:10.1111/bjh.70003
• Papageorghiou AT, Kihara AB, Dunkley-Bent J, et al. New guidelines for the prevention, diagnosis, and treatment of postpartum haemorrhage: ending the geography of risk. Lancet Glob Health. 2025;13(11):e1796-e1798. doi:10.1016/S2214-109X(25)00404-8
• Zheng XL, Al-Housni Z, Cataland SR, et al. 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2025;23(11):3711-3732. doi:10.1016/j.jtha.2025.06.002

PERSPECTIVES & REVIEWS

• Chaigneau M, Bowman M, Guerin A, et al. How genetic advances are being translated into improved diagnostic outcomes for patients with inherited bleeding disorders. Blood Vessel Thromb Hemost. 2025;2(4):100090. doi:10.1016/j.bvth.2025.100090
• Jourdi G, Flaujac C, De Maistre E, et al. Usefulness and Limits of DOAC Removal Agents Based on Activated Charcoal in Thrombophilia Testing: Literature Review and Expert Proposals. Thromb Haemost. 2025. doi:10.1055/a-2695-2674
• Khambaty M, Connors JM, Grawe ES, et al. Society for Perioperative Assessment and Quality Improvement: a narrative review of best practices for perioperative management of patients with bleeding disorders. Br J Anaesth. 2025;135(5):1269-1278. doi:10.1016/j.bja.2025.07.090
• Longacre MM, Ibla JC. TEG and ROTEM: Technology and Clinical Applications, 2026 Update. Am J Hematol. 2025;100(12):2357-2370. doi:10.1002/ajh.70074
• Luo S, Shi J, Lv Q. Advances in nanotechnology for synthetic polymer hemostats: navigating precision hemostasis. Blood Coagul Fibrinolysis. 2025;36(7):328-334. doi:10.1097/MBC.0000000000001378
• Prasannan A, Venkatachalam K, Binesh A. Factor VIII beyond haemophilia: a hidden regulator of venous thrombosis and endothelial dysfunction. Blood Coagul Fibrinolysis. 2025;36(7):335-346. doi:10.1097/MBC.0000000000001385
• Shetty S, Jivani F, Kamble A, et al. Bleeding disorders of unknown cause: A conglomeration of disorders with heterogeneous etiology. Thromb Res. 2025;255:109496. doi:10.1016/j.thromres.2025.109496

CLINICAL TRIALS 

• Alharran AM, Alotaibi TM, Alazmi AM, et al. Effectiveness of Prothrombin Complex Concentrate Versus Fresh Frozen Plasma in Major Cardiac Surgeries: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. 2025;17(10):e94405. doi:10.7759/cureus.94405
• Crichi B, Delrue M, Alsuliman T, et al. Reduced-dose versus full-dose apixaban for extended treatment of cancer-associated venous thromboembolism: A systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Thromb Res. 2025; Oct 14:256:109505. doi:10.1016/j.thromres.2025.109505
• de Lucena LA, Duarte AG, Hespanhol LC, et al. Reduced vs full-dose direct oral anticoagulants for extended treatment of cancer-associated venous thromboembolism: a systematic review and meta-analysis of randomized trials. J Thromb Haemost.  2025; Oct 16:S1538-7836(25)00645-2. doi:10.1016/j.jtha.2025.09.026
• Heeg J, Dobbelstein C, Iorio A, et al. Pharmacokinetic strategies for achieving precise factor VIII control with susoctocog alfa in acquired hemophilia A. J Thromb Haemost. 2025;23(11):3492-3500. doi:10.1016/j.jtha.2025.07.033
• Kim D, Shim J, Choi EK, et al. Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial. JAMA. 2025;334(14):1246-1254. doi:10.1001/jama.2025.14679
• Malec L, Mathias M, Dunn AL, et al. Post hoc analysis of bleeding episodes and clinically relevant pharmacokinetic parameters among children <12 years old with severe hemophilia A receiving once-weekly efanesoctocog alfa prophylaxis in the XTEND-Kids phase 3 multinational trial. J Thromb Haemost. 2025;23(11):3481-3491. doi:10.1016/j.jtha.2025.07.011
• Manco-Johnson M, Brons P, Knoebl P, et al. Real-world use of protein C concentrate for the treatment of patients with protein C deficiency: an international registry. J Thromb Haemost. 2025;23(11):3569-3577. doi:10.1016/j.jtha.2025.07.018
• Ogneva A, Rodina Y, Pershin D, et al. Efficacy and safety of romiplostim and eltrombopag in management of thrombocytopenia in Wiskott-Aldrich syndrome patients. Br J Haematol. 2025;207(4):1558-1564. doi:10.1111/bjh.20182
• Roussel M, Bannelier H, Lebal S, et al. D-Dimer thresholds for diagnosis of pulmonary embolism based on a single question: is it the most likely diagnosis? A prospective, multicentre, open-label, single-arm interventional study. Lancet Respir Med. 2025; Oct 21:S2213-2600(25)00292-9. doi:10.1016/S2213-2600(25)00292-9
• Wu R, Chen Y, Li W, et al. The efficacy, safety, and pharmacokinetics of N8-GP in previously treated Chinese patients with haemophilia A: results from the phase 3b pathfinder10 study. Blood Coagul Fibrinolysis. 2025;36(7):309-317. doi:10.1097/MBC.0000000000001386
• Yamaguchi J, Arashi H, Hagiwara N, et al. Age-Stratified Effect of Rivaroxaban Monotherapy for Atrial Fibrillation in Stable Coronary Artery Disease: A Post Hoc Analysis of the AFIRE Randomized Clinical Trial. JAMA Cardiol. 2025; 10(10):990-999. doi:10.1001/jamacardio.2025.2611

CASE SERIES & RETROSPECTIVE STUDIES

• Al Buraidi R, Al Moosawi M, Al Falahi K, et al. High agreement between one-stage clot-based and chromogenic factor VIII activity assays. Blood Coagul Fibrinolysis. 2025;36(7):318-322. doi:10.1097/MBC.0000000000001384
• Delluc A, Carrier M, Lauw M, et al. Indefinite anticoagulation with reduced-intensity direct oral anticoagulants in patients with splanchnic vein thrombosis. An international practice survey. Blood Coagul Fibrinolysis. 2025;36(8):364-370. doi:10.1097/MBC.0000000000001388
• Godino C, Mazza R, Gaspardone C, et al. Plasma levels measurement of the 4 direct oral anticoagulants in patients with atrial fibrillation at the time of acute thromboembolic and bleeding events. J Thromb Haemost. 2025;23(11):3515-3526. doi:10.1016/j.jtha.2025.06.031
• Göl DK, Gök V, Yilmaz E, et al. Human plasma-derived plasminogen replacement in type 1 plasminogen deficiency: a pediatric case with multisystemic manifestation. Blood Coagul Fibrinolysis. 2025;36(8):386-388. doi:10.1097/MBC.0000000000001391
• Howells L, Lissack M, Wykes C, et al. Recombinant ADAMTS-13 for congenital and immune thrombotic thrombocytopenic purpura in pregnancy. Blood Vessel Thromb Hemost. 2025;2(4):100101. doi:10.1016/j.bvth.2025.100101
• Lim MY, Cogan JC, Cromwell C, et al. Comparative analysis of perioperative management of antiplatelet agent guidelines across US institutions. Thromb Res. 2025;255:109493. doi:10.1016/j.thromres.2025.109493
• Poli D, Parisi R, Antonucci E, et al. Low-dose direct oral anticoagulants for secondary prevention in patients at high risk for recurrence due to history of recurrent venous thromboembolic events or severe thrombophilia: a retrospective analysis of the Italian Survey on anTicoagulated pAtients RegisTry 2. J Thromb Haemost. 2025;23(11):3625-3632. doi:10.1016/j.jtha.2025.07.034
• Wei X, Wu J, Zhang G, et al. Clinical Study on the Assessment of Infection-Induced Disseminated Intravascular Coagulation (DIC) and Its Prognosis in Neonates by Tissue-Type Plasminogen Activator-Plasminogen Activator Inhibitor-1 Complex. Int J Lab Hematol. 2025;47(6):1137-1146. doi:10.1111/ijlh.14516

RESEARCH

• Akkaya E, Koc BS, Kucuksezer UC, et al. Understanding of the roles of CD4 + CD25 + T cells and Tregs in development of anti-FVIII in hemophilia A: insights for inhibitor development prevention. Blood Coagul Fibrinolysis. 2025;36(8):371-380. doi:10.1097/MBC.0000000000001393
• Dupuy A, Qi M, Fenwick JCL, et al. Endo-chip laser-induced thrombus formation: a vessel-on-chip model for in vitro testing of antithrombotic agents. Blood Vessel Thromb Hemost. 2025;2(4):100096. doi:10.1016/j.bvth.2025.100096
• Hordijk S, Groten SA, Bürgisser PE, et al. A novel cause of type 1 von Willebrand disease: impaired exocytosis of Weibel-Palade bodies due to biallelic MADD variants. Blood. 2025;146(17):2133-2144. doi:10.1182/blood.2024027935
• Hoornstra IMS, Zhao J, Middelveld H, et al. Procoagulant off-target effect of the direct oral anticoagulant reversal agent Andexanet alfa. Blood Vessel Thromb Hemost. 2025;2(4):100100. doi:10.1016/j.bvth.2025.100100
• Mir TH, Patell R, Freed JA. M protein and the evolving spectrum of platelet-activating anti-PF4 disorders and MGTS and their linkage. Blood Vessel Thromb Hemost. 2025;2(4):100093. doi:10.1016/j.bvth.2025.100093
• Morris JJ, Parsons NA, Wilhelm AR, et al. Factor IXa and factor X influence factor VIIIa stability and inactivation mechanisms in vitro and in vivo. Blood. 2025;146(18):2259-2271. doi:10.1182/blood.2024027705

METHODS

• Anakmeteeprugsa S, Gonzalez-Fiol A, Garay A, et al. Baseline values for Quantra QPlus in healthy pregnant women at term and comparison to standard laboratory coagulation values: a prospective observational study. BMC Pregnancy Childbirth. 2025;25(1):826. doi:10.1186/s12884-025-07927-z
• Hayward CPM, Al Dawood R, Wice L, et al. How Trustworthy is Light Transmittance Platelet Aggregometry With Low Platelet Count Samples? Insights From Test Replicates and Retrospective Analysis of Several Decades of Diagnostic Samples. Int J Lab Hematol. 2025;47(6):1147-1157. doi:10.1111/ijlh.14518
• Herb A, Wimmer J, Mauvieux L, et al. Pitfalls in Argatroban Monitoring: Heparin Interference With Dilute Thrombin Time Assays. Int J Lab Hematol. 2025;47(5):989-991. doi:10.1111/ijlh.14505
• Horner K, Kitchen S. Evaluation of Clauss Fibrinogen Assay Clot Waveform Analysis for the Detection of Dysfibrinogenemia on Sysmex CN-6000. Int J Lab Hematol. 2025;47(5):915-922. doi:10.1111/ijlh.14484
• Isiklar OO, Kocaturk E, Oner KS, et al. Uncovering Hidden Traces of K₂EDTA Contamination in Citrated Blood Samples: A Novel Approach Using Fibrinogen Clot Waveform Graphs. Int J Lab Hematol. 2025;47(6):1158-1170. doi:10.1111/ijlh.14519
• Kamali S, Dave M, Raheja P, et al. Evaluation of International Council for Standardization in Haematology Recommendations on Activated Partial Thromboplastin Time Mixing Tests Using an Automated Haemostasis Analyser. Int J Lab Hematol. 2025;47(6):1178-1185. doi:10.1111/ijlh.14537
• Kumano O, Ieko M, Hashiguchi T, et al. Variability of Argatroban Effects on the Multiple APTT Reagents in High and Low Coagulation Activity Samples. Int J Lab Hematol. 2025;47(5):923-930. doi:10.1111/ijlh.14488
• Lund M, Heenkenda MK, Laine C, et al. A global hemostasis analyzer for kinetic characterization of clot formation, retraction, and lysis. Thromb Res. 2025;255:109480. doi:10.1016/j.thromres.2025.109480
• Martinuzzo ME, Berger CS, Sueldo E, et al. Concentration Estimation of Apixaban and Rivaroxaban in Plasma From Patients Through Heparin-Calibrated Anti-Xa Assay Generated Different Results by Using 3 Reagent/Calibrators/Instrument Systems. Int J Lab Hematol. 2025;47(5):931-937. doi:10.1111/ijlh.14497
• Rial C, Gendron N, Le Beller C, et al. Evaluation of an IgG anti-PF4/H chemiluminescent immunoassay in the diagnosis of heparin-induced thrombocytopenia. Blood Vessel Thromb Hemost. 2025;2(4):100084.  doi:10.1016/j.bvth.2025.100084
• Saadalla A, Doyle K, Moser K, et al. Determination of Fibrinogen Ratio Cutoff Limits Using Indirect Reference Interval Methodology. Int J Lab Hematol. 2025;47(6):1171-1177. doi:10.1111/ijlh.14526
• Tamura T, Yokoyama T. The TEG6s-Derived R ratio accurately reflects the anti-Xa level after cardiac surgery: A proof-of-concept study. Perfusion.  2025;9:2676591251388353. doi:10.1177/02676591251388353